Physician

Ryan Stuart Drake, DO

According to 2025 Medicare claims, Ryan Drake, DO (NPI: 1326256462) practices neurology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is NEUROCARE CENTER INC (NPI: 1689769572; TIN: 341257807) and primary practice location at 44718-2531. Drake is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Drake's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 651 traditional Medicare patients, billed 41,749 HCPCS/CPT codes, and received $258,474 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,965 prescription claims across 973 beneficiaries totaling $2,862,701 in drug costs, led by Ingrezza (Valbenazine Tosylate). 2021 DME data shows 11 claims. Open Payments data shows 409 records totaling $640,226. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,155,532 to $2,862,701. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,065 and ending at $2,107.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	979	9,269	$195,847
2016	1,039	14,055	$231,223
2017	1,079	14,177	$229,930
2018	1,025	8,800	$198,097
2019	861	7,975	$155,203
2020	838	8,875	$146,850
2021	919	11,677	$216,093
2022	856	11,500	$191,209
2023	774	15,504	$214,339
2024	651	41,749	$258,474

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	566	3,494	$1,155,532
2016	599	3,343	$1,328,902
2017	639	3,342	$1,519,883
2018	709	3,613	$1,706,444
2019	686	3,321	$1,267,354
2020	793	4,212	$1,516,465
2021	908	4,675	$1,860,485
2022	849	3,850	$1,815,922
2023	847	4,258	$1,626,485
2024	973	4,965	$2,862,701

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	39	$89,791
2020	N/R	N/R	N/R
2021	N/R	11	$296
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	100	100	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	438	665	$82
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	103	110	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	488	703	$13
J0586	Injection, abobotulinumtoxina, 5 units	43	13,650	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ingrezza	Valbenazine Tosylate	24	711	$271,693
Austedo Xr	Deutetrabenazine	22	654	$165,325
Botox	Onabotulinumtoxina	86	7,512	$113,060
Avonex Pen (4 Pack)	Interferon Beta-1a	13	364	$107,514
Austedo	Deutetrabenazine	18	516	$104,802

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	336	$65,671	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	73	$574,554	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ryan Stuart Drake, DO?

Tedicare shows public-source Medicare data for Ryan Stuart Drake, DO (NPI 1326256462), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ryan Stuart Drake, DO have ACO affiliation data?

Ryan Stuart Drake, DO is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Ryan Stuart Drake, DO?

Ryan Stuart Drake, DO is linked to NEUROCARE CENTER INC (billing NPI 1689769572) in the available physician profile data.

Does Ryan Stuart Drake, DO have Open Payments data?

Ryan Stuart Drake, DO has 409 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.